Hard-core drugs: Recent structural and spectroscopic studies demonstrate the versatility of organometallic drug candidates, for example, as novel protein kinase inhibitors and hormone-independent breast cancer prodrugs. The presence of a transition-metal center in such systems allows both the organization of ligands in 3D space (see picture) and the control of redox-activation processes in biological systems.
No takes yet. Share an insight, caveat, or question.
Schatzschneider et al. (2006) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: